<?xml version="1.0" encoding="UTF-8"?>
<p id="P31">Oral ganciclovir may be used to prevent CMV in patients with AIDS; however, the benefit of this strategy is not as pronounced in the era of highly active antiretroviral therapy. Although IV and oral ganciclovir have also been used to prevent CMV disease in transplant recipients, valganciclovir is currently the preferred drug for this indication.
 <sup>
  <xref ref-type="bibr" rid="R60">60</xref>,
  <xref ref-type="bibr" rid="R61">61</xref>,
  <xref ref-type="bibr" rid="R70">70</xref>
 </sup> Intravenous ganciclovir is also used as a first-line treatment of CMV disease in bone marrow and solid organ transplant recipients.
 <sup>
  <xref ref-type="bibr" rid="R61">61</xref>
 </sup>
</p>
